Video

Dr. Shaughnessy Discusses Stem Cell Mobilization in Lymphomas

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses stem cell mobilization in patients with lymphomas.

There are a variety of chemotherapy agents available to treat patients with different types of lymphoma, and physicians can still mobilize adequate stem cells, even with the newer chemotherapy regimens being used.

Physicians should also be aware of the risk of toxicity to underlining hematopoietic stem cells and not being able to collect adequate number of stem cells.

More studies are necessary, according to Shaughnessy, to better understand if enough stem cells are being given to patients and if this will impact patients better in the future.

<<< 2019 Transplantation and Cellular Therapy Meetings

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School